PPBT Quote, Financials, Valuation and Earnings

Compugen Ltd. has a net margin of -- compared to Purple Biotech Ltd.'s net margin of -369.06%. Purple Biotech Ltd.'s return on equity of -10.31% beat Compugen Ltd.'s return on equity of -51.8%.

Purple Biotech Ltd. has a consensus price target of $34.00, signalling upside risk potential of 4705.65%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 311.18%. Given that Purple Biotech Ltd. has higher upside potential than Compugen Ltd., analysts believe Purple Biotech Ltd. is more attractive than Compugen Ltd..

Purple Biotech Ltd. has a beta of 0.599, which suggesting that the stock is 40.065% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.

Purple Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Purple Biotech Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.

Purple Biotech Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Purple Biotech Ltd.'s net income of -$1.3M is higher than Compugen Ltd.'s net income of -$7M. Notably, Purple Biotech Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Purple Biotech Ltd. is -- versus 20.31x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Nasus Pharma has a net margin of -- compared to Purple Biotech Ltd.'s net margin of --. Purple Biotech Ltd.'s return on equity of -10.31% beat Nasus Pharma's return on equity of --.

Purple Biotech Ltd. has a consensus price target of $34.00, signalling upside risk potential of 4705.65%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Purple Biotech Ltd. has higher upside potential than Nasus Pharma, analysts believe Purple Biotech Ltd. is more attractive than Nasus Pharma.

Purple Biotech Ltd. has a beta of 0.599, which suggesting that the stock is 40.065% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Purple Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Purple Biotech Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.

Purple Biotech Ltd. quarterly revenues are --, which are larger than Nasus Pharma quarterly revenues of --. Purple Biotech Ltd.'s net income of -$1.3M is higher than Nasus Pharma's net income of --. Notably, Purple Biotech Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Purple Biotech Ltd. is -- versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

BiomX, Inc. has a net margin of -- compared to Purple Biotech Ltd.'s net margin of --. Purple Biotech Ltd.'s return on equity of -10.31% beat BiomX, Inc.'s return on equity of -160.84%.

Purple Biotech Ltd. has a consensus price target of $34.00, signalling upside risk potential of 4705.65%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 18632.39%. Given that BiomX, Inc. has higher upside potential than Purple Biotech Ltd., analysts believe BiomX, Inc. is more attractive than Purple Biotech Ltd..

Purple Biotech Ltd. has a beta of 0.599, which suggesting that the stock is 40.065% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.

Purple Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Purple Biotech Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.

Purple Biotech Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. Purple Biotech Ltd.'s net income of -$1.3M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Purple Biotech Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Purple Biotech Ltd. is -- versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.